8,759
Total Claims
$2.2M
Drug Cost
947
Beneficiaries
$2,345
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+54%
Cost per patient vs peers
$2,345 vs $1,524 avg
+57%
Brand preference vs peers
21.4% vs 13.7% avg
Brand vs Generic
79% generic
Brand: 1,872 claims · $2.0M
Generic: 6,887 claims · $201K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,004 | $1.2M |
| Rivaroxaban | 162 | $218K |
| Evolocumab | 196 | $151K |
| Empagliflozin | 139 | $136K |
| Sacubitril/Valsartan | 89 | $135K |
| Dronedarone Hcl | 25 | $56K |
| Ticagrelor | 52 | $51K |
| Alirocumab | 46 | $39K |
| Azilsartan Med/Chlorthalidone | 23 | $17K |
| Metoprolol Succinate | 680 | $14K |
| Ezetimibe | 381 | $14K |
| Dapagliflozin Propanediol | 13 | $13K |
| Atorvastatin Calcium | 757 | $13K |
| Valsartan | 377 | $11K |
| Clonidine | 29 | $11K |
Prescribing Profile
59
Unique Drugs
$1.7M
Patient Profile
77
Avg Age
53%
Female
1.63
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data